# Eupraxia Pharmaceuticals Inc.: Form 40-F for the period ended Dec 31, 2025

- Company: [Eupraxia Pharmaceuticals Inc.](/companies/eprx.md) (CIK 1581178)
- Form: 40-F
- Filed: 2026-03-13
- Accepted by EDGAR: Mar 12, 2026, 21:18 ET
- Period: 2025-12-31
- Accession: 0001193125-26-104765
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1581178/000119312526104765/d78249d40f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1581178/000119312526104765/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2025-01-01 to 2025-12-31 | $0 | us-gaap:Revenues |
| Research and development | 12 months, 2025-01-01 to 2025-12-31 | $21.3m | us-gaap:ResearchAndDevelopmentExpense |
| Interest expense | 12 months, 2025-01-01 to 2025-12-31 | $0 | us-gaap:InterestExpense |
| Income tax | 12 months, 2025-01-01 to 2025-12-31 | $19.1k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2025-01-01 to 2025-12-31 | −$38.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2025-01-01 to 2025-12-31 | −$1.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2025-01-01 to 2025-12-31 | −$1.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2025-01-01 to 2025-12-31 | 39,956,133 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2025-01-01 to 2025-12-31 | −$28.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2025-12-31 | $80.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-12-31 | $85.1m | us-gaap:AssetsCurrent |
| Total assets | at 2025-12-31 | $86.2m | us-gaap:Assets |
| Current liabilities | at 2025-12-31 | $5.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2025-12-31 | $5.7m | us-gaap:Liabilities |
| Shareholders' equity | at 2025-12-31 | $82.0m | us-gaap:StockholdersEquity |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1581178/000119312526104765/d78249d40f.htm

Filed Mar 13, 2026.
Source: SEC EDGAR, the filing index for accession 0001193125-26-104765. Last ingested by Listed: Nov 13, 2026, 16:45 ET. No prices; not investment advice.